Glutamine Metabolism and Prostate Cancer

Area of Science:

• Oncology
• Metabolic pathways
• Cancer biology

Background:

• Glutamine (Gln) is crucial for prostate cancer (PCa) cell proliferation and survival.
• PCa cells exhibit a high dependency on exogenous Gln, unlike normal prostate cells.
• Key oncogenes (MYC, AR, mTOR) regulate Gln metabolism in PCa, driving therapy resistance and progression.

Purpose of the Study:

• To review the role of glutamine in prostate cancer progression and therapy resistance.
• To explore glutamine metabolism as a therapeutic target for PCa.
• To provide insights into ongoing clinical trials for Gln catabolism inhibitors in PCa.

Main Methods:

• Literature review focusing on glutamine metabolism in prostate cancer.
• Analysis of oncogene-driven Gln metabolism pathways.
• Summary of current clinical trial data on Gln inhibitors.

Main Results:

• Inhibition of Gln catabolism significantly impairs PCa growth, survival, and tumor-initiating capacity.
• Targeting Gln metabolism sensitizes PCa cells to radiotherapy.
• Gln metabolism is a critical factor in the development of castration-resistant PCa.

Conclusions:

• Targeting glutamine metabolism represents a promising therapeutic strategy for prostate cancer.
• Further research into PCa's metabolic interactions with its microenvironment is needed for clinical translation.
• Gln catabolism inhibitors are being evaluated in clinical trials for various solid tumors, including PCa.